Workshop on process validation



Similar documents
Workshop on process validation

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

Guideline on Process Validation

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

Guidance for Industry

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *

Process Validation: Practical Aspects of the New FDA Guidance

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Quality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party

Manufacturing process of biologics

PHARMACEUTICAL DEVELOPMENT

Workshop B Control Strategy

PHARMACEUTICAL QUALITY SYSTEM Q10

Workshop A Design Space (DS)

Quality by Design (QbD) Overview

Questions and answers on post approval change management protocols

ICH guideline Q10 on pharmaceutical quality system

Control Strategy Case Studies

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

Introduction to Q10 Pharmaceutical Quality System

Guidance for Industry

Guidance for Industry. Q10 Pharmaceutical Quality System

State of Control Over the Lifecycle and Process Validation (New and Legacy Products)

Multivariate Tools for Modern Pharmaceutical Control FDA Perspective

Lifecycle CMC Management: ICH Q12 Progress to date

ICH Public Meeting. Joseph C. Famulare. October 2, Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

ICH Q10 Pharmaceutical Quality System (PQS)

The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

PHARMACEUTICAL REFERENCE STANDARDS

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Questions and answers on post approval change management protocols

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

ICH Q10 and Change Management: Enabling Quality Improvement

White paper: FDA Guidance for Industry Update Process Validation

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

GMP/Regulatory Environment in the

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Guidance for Industry

FDA Guidance for Industry Update - Process Validation

Best Practice In A Change Management System

Assay Qualification Template for Host Cell Protein ELISA

Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

Work plan for GMP/GDP Inspectors Working Group for 2016

ICH Q10 - Pharmaceutical Quality System

Guideline on stability testing for applications for variations to a marketing authorisation

Pharmaceutical Quality Systems: US Perspective

The Effective Management of Change Across the ICHQ10 Lifecycle

Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

EMA Update Clinical Trials

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

Taking a Leap Toward Global Supply Chain Efficiency

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

Validation and Calibration. Definitions and Terminology

What is Process Validation?

Implementing New USP Chapters for Analytical Method Validation

EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

Working with ICH Quality Guidelines - the Canadian Perspective

Questions & answers on signal management

What to control? CQAs and CPPs

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

QbD Considerations for Analytical Methods - FDA Perspective

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation)

Diogo Filipe Lopes Ferreira

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

Q8(R2): Pharmaceutical Development

Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers

Industry Implications of Pharmaceutical Quality ICH Guidelines

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014

MEDICAL LABORATORY TECHNICIAN COMPETENCY PROFILE

GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme

Annex 2. WHO guidelines on quality risk management. 1. Introduction Glossary Quality risk management process 70

Design of Experiments for Analytical Method Development and Validation

A Stability Program for the Distribution of Drug Products

Impact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11

Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?

Guideline on good pharmacovigilance practices (GVP)

Recent Updates on European Requirements and what QPs are expected to do

ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK

IMPURITIES IN NEW DRUG PRODUCTS

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation

Lifecycle Management of Analytical Procedures; What is it all about? Jane Weitzel Independent Consultant

Transcription:

Workshop on process validation General concepts on process validation Kowid Ho

Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture of medicinal products (i.e. scope of Q6B) Address data requirement for process validation/evaluation for submission of a marketing authorisation application or variation. Process Validation can be based on a traditional or enhanced approach to process development. Traditional and enhanced approaches are not mutually exclusive. A company can use either a traditional approach or an enhanced approach to process validation, or a combination of both. 1

Process development Not considered as part of process /validation But: Comprises an essential prerequisite in defining the criteria and conditions to be addressed in process validation studies. Should identify which material attributes (e.g., of raw materials, starting materials, reagents, solvents, process aids, intermediates) and process parameters that should be further evaluated during process evaluation/validation studies. Risk assessment including documented prior knowledge should be used to identify and justify the material attributes and process parameters with the potential for having an effect on drug substance CQAs and/or process performance. Preliminary acceptance criteria or limits should be defined Difference with "process characterisation"? 2

Process validation (ICHQ11) Process validation is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a drug substance or intermediate meeting its predetermined specifications and quality attributes. Process validation can include the collection and evaluation of data, from the process design stage throughout production, that establish scientific evidence that a process is capable of consistently delivering a quality drug substance. 3

Process validation Normally include evaluation and verification of process steps and the complete process Evaluation and verification activities: often confounded in a same study; not always necessary to make a difference between these activities as long as the evidences required for their demonstration are appropriately presented. Controls (e.g. quality attribute, performance indicator, process parameter, controls implicit in the design of the process): normally go beyond the routine control system performed during routine production. What is the Industry understanding of process performance indicators/parameters for the upstream and downstream processes? Would these terms differ from consistency indicators/parameters? 4

Process validation Data collected from studies representative of the final commercial process Contribution of data from small-scale studies to the overall validation package will depend upon demonstration that the small-scale model is an appropriate representation of the proposed commercial scale Data derived from commercial-scale batches should confirm results obtained from small scale studies used to generate data in support of process validation. Where appropriate, prior knowledge could be used to support some claims 5

Process evaluation Process evaluation studies: should provide evidence that, when operating in accordance with conditions described in process description, the complete manufacturing process and each step/operating unit have been appropriately designed to obtain a product of the intended quality. should include the evaluation of the ability of each step to obtain output of desired quality at small and/or full scale as appropriate. the results, demonstrating that when operating in accordance with the defined controls for material attributes and process parameters, the process is able to deliver quality attributes and process performance results in compliance with their pre-defined ranges, should be presented. 6

Process evaluation Where appropriate, evaluation of selected step(s) operating in worst case and/or abnormal conditions (e.g. cumulative hold time, spiking challenge) could be performed to support or demonstrate the robustness and the capability of the process to deliver product of the intended quality in these conditions. In some cases, these activities could be built into process verification studies. Depending on the level of evidence provided to demonstrate the high performance of the step(s) and the relevance of experimental model with regards to the final process, these studies could leverage data requirements for process verification (e.g. reduced number of batches) and/or control strategy (e.g. alternative approach to end product testing). Process evaluation: main data to support PAR? 7

Process verification Process verification studies should confirm that the final manufacturing process (i.e. full scale commercial process) performs effectively and is able to produce a drug substance or intermediate meeting its predetermined controls and acceptance criteria. Process verification data (e.g. process step results, batch analyses) should be presented in the MAA on an appropriate number of batches (to confirm consistency) produced with the commercial process and scale Process verification studies should normally be completed and included in the Marketing Authorisation Application. In some circumstances, concurrent validation could exceptionally be considered. As an alternative approach, continuous process verification could facilitate registration of concurrent validation studies and/or manufacturing process changes throughout the remainder of the product lifecycle. Process verification: main data to set Normal Operating Ranges? 8

Process validation For process evaluation and verification, is it necessary to have a higher level and frequency of sampling and testing as compared to routine manufacture? Would you present this data in the dossier? 9

Continued process verification Subsequent to successful process validation activities for MAA Monitor product quality and process performance to ensure that a state of control is maintained throughout the commercial part of the product lifecycle. To be performed in compliance with EU GMP Presentation of continued process verification program in MAA to support process validation? Include extended control system performed at appropriate frequency, in accordance to internal limits? acceptance limits? Include protocols covering aspects that will be verified on an ongoing basis? Periodicity? 10

Continued vs Continuous Process Verification ICH Q8: Continuous Process Verification: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. Merriam-Webster: Continuous: marked by uninterrupted extension in space, time, or sequence Continued: lasting or extending without interruption resumed after interruption Continuously: continuing without stopping : happening or existing without a break or interruption 11

Continued vs Continuous Process Verification ICH IWG PtC: CPV can be applied to an entire process, or to portions of a process, together with traditional process validation approaches. Generally, for initial process validation, CPV is more appropriate when an enhanced development approach has been applied. However, it can also be used when extensive process knowledge has been gained through commercial manufacturing experience QWP draft guideline on process validation (29/03/2012): CPV: Risk based, real time approach to verify 12

Continued vs Continuous Process Verification QWP draft guideline on process validation (29/03/2012): Continued Process validation: documented evidence that the process remains in state of control during commercial manufacture ICH Q11: The development and improvement of a drug substance manufacturing process usually continues over its lifecycle. Manufacturing process performance, including the effectiveness of the control strategy, should be periodically evaluated. ICH Q7: Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. 13

Continued vs Continuous Process Verification Aim Frequency Continous Process Verification - Initial demonstration and/or maintenance of a state of control - uninterrupted - timely manner Continued (/ongoing?) Process Verification - maintenance of a state of control - resumed after interruption - periodic Testing/Monitoring - Not limited to CPP and CQA - Include process performance Enabler - PAT tools (MSPC, inline control ) - Extensive process knowledge and understanding - GMP compliance - Control strategy during product lifecycle (ex. design space verification) 14

MANUFACTURING PROCESS DEVELOPMENT, EVALUATION & VALIDATION S.2.6 Development S.2.5 Evaluation / Validation Continued process verification - Development strategy - CQA, CPP identification - Range studies - DOE - MVA / univariate analysis - interaction studies - Design space development - lot/process filiation - Comparability - Evaluation of each operating unit and complete process at target - Evaluation of selected steps off target - Verification of reproducibility of all steps at target on appropriate number of batches - Continuous process verification (alternative) - Documented evidence of process capability - Demonstration of validated state / state of control INSPECTION DATA TO BE SUBMITTED IN MAA CONVENTIONAL ENHANCED ASSESSMENT QUALITY SYSTEM Q7 Q10